BIA responds to 2021 Budget

Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA), said: "The COVID-19 pandemic has shown the strategic necessity for the UK to have a thriving domestic life sciences and biotech sector. Companies and researchers from across the UK have led in the global effort to develop, manufacture and deploy the COVID-19 vaccines, therapies and diagnostics needed to re-open the global economy. As the Prime Minister made clear last week, this successful public-private partnership is the formula for our country’s prosperity for years to come, a strong and active government investing massively in science and technology, coupled with a dynamic enterprise economy.

WuXi AppTec Completes Acquisition of OXGENE to Further Strengthen Cell and Gene Therapy Service Offerings for Global Customers

WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, today announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies

BIA analysis of 2021 Budget

The Chancellor has said that business support measures such as Furlough will continue, and more money has been made available to vaccine programmes. But alongside these measures to mitigate the impact of the pandemic, there was a promise of more investment in science and tech scale-ups, improvements to R&D tax credits to incentivise cutting edge science to be conducted in the UK, and rule changes to make it easier to list on the London Stock Exchange.

Coulter Partners secures Chief Finance Officer and Non-Executive Director for Optimapharm

Coulter Partners was delighted to partner again recently with Optimapharm to secure the appointments of Walter Miller as Chief Finance Officer and Dr Charles Woler, M.D., Ph.D., as Non-Executive Director. Optimapharm is a contract research organization (CRO) managing clinical trials on behalf of leading biotech, pharma and medical devices companies in 27 countries across EMEA.

CN Bio awarded Innovate UK grant to develop single and multi-organ models for COVID-19 research

Cambridge, UK, 02 March 2021: CN Bio, a leading developer of single and multi-organ microphysiological systems (MPS), otherwise known as organ-on-a-chip, today announced it has received a grant from Innovate UK, the UK’s innovation agency, to develop human-relevant MPS to advance investigations into SARS-CoV-2 infection. The funding will be used to develop and test advanced cell culture models that represent different regions of the lung and subsequently linking these models to other organ systems, such as liver and gut, to inform the rapid development of novel therapeutics.

Vaccitech Appoints Two Independent Board Directors

Oxford, UK – Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the appointment of two new independent directors to its Board of Directors.

Lisa Deschamps Joins Verona Pharma as Non-Executive Director

LONDON and RALEIGH, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces, effective March 1, 2021, Ms. Lisa Deschamps has joined the board as a Non-Executive Director.

CEO Update | Monday 01 March

If you want to understand how central life sciences entrepreneurialism is to this Government’s economic strategy, then this pre-Budget Facebook video by Boris Johnson makes for interesting viewing.

Pharmaron Acquires State-of-the-Art Biomanufacturing Site in the United Kingdom from AbbVie

Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) (“Pharmaron”) announced today that it has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions.

NovaBiotics announces latest licensing deal

Licensing Deal for NP213 Nail Fungus Treatment is Another Key Milestone for NovaBiotics